Manish Goel - SEBI Registered Investment Advisor

About Manish Goel

SEBI Registered Investment Advisor • Chartered Accountant

383 Articles Published

Manish Goel is a Chartered Accountant, SEBI-registered Investment Advisor, and founder of Multibagger Shares. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

May 12, 2026
Hero header: 'Director Remuneration as a Percentage of' with a green timeline showing FY21–FY25 milestones (Compliance, Disclosure, Audit clean, Board change, All boxes) on a dark blue gradient background.

Director Remuneration as a Percentage of PAT: The Companies Act Section 197 Governance Test Every Indian Long-Term Investor Must Master

Companies Act 2013 Section 197 caps managerial pay at 11% of PAT. Learn how to read this under-used governance ratio in 15 minutes — illustrated by Titan Biotech FY25's ~₹4.56 Cr director remuneration alongside 14 board meetings, an independent chair, ~103% CFO/Operating Profit and a ~29% ten-year PAT CAGR.
May 12, 2026
Hero section with Time Arbitrage title and italic subtitle; a 2x2 color grid: top-left Trader (gray), top-right COMPOUNDER (green), bottom-left Drift (light gray), bottom-right Speculator (orange).

Time Arbitrage: Why Stretching Your Holding Period to Five and Ten Years Is the Single Greatest Edge a Private Indian Investor Has Over Institutional Money

Why time arbitrage — the structural edge of holding quality businesses for five to ten years while institutional money is forced to optimise for the next 90 days — is the rarest source of edge in Indian value investing, illustrated by Titan Biotech's FY25 audited numbers.
May 11, 2026
Hero header with title 'The Halo Effect' and subtitle; below is a two-by-two colored grid labeled Lucky (gray), Disciplined Investor (green), Confused (light gray), Bias-Trapped (orange).

The Halo Effect: Thorndike’s 1920 Discovery and Phil Rosenzweig’s 2007 Warning

Edward Thorndike documented the halo effect in 1920; Phil Rosenzweig's 2007 book showed it runs backward in business commentary. We unpack the five Indian retail-investor halo channels, share a five-step de-haloing checklist, and use Titan Biotech FY25's nine decorrelated disclosed markers as an illustrative anti-halo process case study.
May 11, 2026
Bar chart of 10-Year Revenue CAGR, FY20–FY25; FY25 is shown in green at 11% with end values 28, 26, 22, 18, 14, 11

10-Year Revenue CAGR: The Foundational Top-Line Compounding Test Every Indian Long-Term Investor Must Master

How to read a 10-year Revenue CAGR through four disciplined lenses — illustrated with Titan Biotech FY25 audited numbers (~15% Revenue CAGR, ~29% PAT CAGR, ~103% CFO/OP, Rs.3 Cr borrowings). Educational only.
+91-8448836436